HCMV jogs the ‘memory’ of NK cells in HBV

The treatment paradigm in hepatitis B virus (HBV) is rapidly transforming with many new viral and immune therapies entering the clinical trial pipeline. Although many of the immune targets focus on restoration of the exhausted virus-specific T cell response1 an increasing body of work makes a case for natural killer (NK) cell-based immune therapies and vaccines.2 Advances in NK cell biology have revealed that these ‘innate’ cells may also possess adaptive features. These cells ‘sitting-on-the-fence’ of innate-adaptive immunity, undergo significant changes in their repertoire during differentiation.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research